We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

13 hedge funds and large institutions have $520K invested in Avenue Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

30% more funds holding

Funds holding: 10 → 13 (+3)

32% less capital invested

Capital invested by funds: $766K → $520K (-$246K)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$638K
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$129K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$115K
4
VF
Virtu Financial
New York
+$78.7K
5
Citigroup
Citigroup
New York
+$40.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$362K
2
Two Sigma Investments
Two Sigma Investments
New York
-$145K
3
TSS
Two Sigma Securities
New York
-$143K
4
TRCT
Tower Research Capital (TRC)
New York
-$14K

ATXI Hedge Fund Activity: Q4 2022 in Review

13 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2022, worth a combined $520K — down 32% from $766K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ATXI positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $638K. The largest seller was Citadel Advisors, exiting entirely with an estimated $362K sold.

  • 13 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2022, up from 10 in Q3 2022.
  • Funds reported $520K of Avenue Therapeutics, Inc. Common Stock stock for Q4 2022, down 32% quarter-over-quarter.
  • 7 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2022 and 4 closed out, a net change of +3 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2022 was Sabby Management, an estimated $638K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2022 was Citadel Advisors, an estimated $362K sold.

Based on aggregated 13F filings for Q4 2022.